omaDex on November 15. Mr. Spengler was previously the Executive Vice President and Chief Financial Officer of MGI PHARMA, Inc. from April 2006 until January 2008, and was Senior Vice President, International & Corporate Development of MGI PHARMA from October 2005 to April 2006. From July 2004 to October 2005, Mr. Spengler was Executive Vice President and Chief Financial Officer of Guilford Pharmaceuticals Inc. prior to its acquisition by MGI PHARMA in October 2005. From May 2002 to June 2004, Mr. Spengler was President, Chief Operating Officer and director of Osteoimplant Technology, Inc. Mr. Spengler was previously a Vice President of Finance at Black & Decker, and prior to that spent 14 years in various finance, planning and business development positions at Bristol Myers Squib. Mr. Spengler currently serves on the Board of Directors of Endo Pharmaceuticals, a publicly traded pharmaceutical company. He holds a BA in Economics from Yale University and an MBA from New York University's Stern School of Business.
About ChromaDexChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. Among other things, the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure™ pterostilbene (http://www.pteropure.com/) as a result of its exclusive worldwide patent rights for pterostilbene. For more information, visit http://www.chromadex.com/ or follow ChromaDex on Twitter @ChromaDex.
Forward-Looking StatementsAny statementPage: 1 2 3 Related biology technology :1
. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene2
. ChromaDex Launches pTeroPure Pterostilbene3
. ChromaDex Announces 2008 Year End Financial Results4
. ChromaDex Announces Second Quarter 2008 Financial Results5
. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications6
. Castle Access Names New Managing Director7
. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer8
. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO9
. RF Technologies® Names Mark Harwood New President10
. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 201011
. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference